Milestone Pharmaceuticals

Headquartered in Quebec, an emerging biotechnology market, the company is a clinical stage cardiovascular drug development company developing novel small molecule therapeutics based on clinically validated mechanisms. Milestone’s lead product, MSP-2017, is a novel and potent short-acting calcium channel antagonist for the treatment of acute episodes of paroxysmal supraventricular tachycardia (PSVT) in an unmonitored setting. MSP-2017 is a derivative of verapamil, an approved drug for the target indication, but is expected to have a better safety profile.

Milestone is premised on this unmet medical need – currently there are no competing short-acting products for terminating acute PSVT episodes in an unmonitored setting.

Milestone Pharmaceuticals

Montreal, Quebec

Website

NASDAQ

MIST

05.09.2019
Milestone Pharmaceuticals Announces Pricing of Upsized Initial Pu…

Read More

10.25.2018
Milestone Pharmaceuticals Announces $80 Million Private Financing

Read More